Table 1.
6 h after LPS | 18 h after LPS | |
---|---|---|
|
||
% of control value | % of control value | |
GSH (μmol/gm) | 60 ± 3* | 49 ± 8.4* |
mRNA levels | ||
MAT1A | 155 ± 13** | 242 ± 30† |
MAT2A | 181 ± 19** | 420 ± 40* |
GNMT | 48 ± 7* | 35 ± 6* |
GCLC | 52 ± 5** | 38 ± 4† |
GCLM | 38 ± 5* | 34 ± 4* |
GS | 62 ± 10** | 55 ± 4† |
iNOS | 22941 ± 9005** | 6057 ± 1029* |
IL-10 | 2189 ± 486† | 3234 ± 693* |
IL-1β | 1892 ± 348† | 262 ± 17† |
Enzyme activity | ||
MATI/III | 53.5 ± 3.2* | 58 ± 11** |
Abbreviations: GCLC, glutamate-cysteine ligase catalytic; GCLM, glutamatecysteine ligase catalytic and modifier subunit; GNMT, glycine N-methyltransferase; GS, glutathione synthetase; GSH, glutathione; IL, interleukin; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MAT, methionine adenosyltransferase.
Results are mean ± s.e. from 5 to 12 determinations for each group. Hepatic GSH levels, mRNA levels, and MATI/III activity were measured as described in ‘Materials and Methods’ 6 and 18 h following LPS administration and expressed as % of control values.
P < 0.001,
P < 0.05,
P < 0.01 vs control.